Business Context and Reporting Period
This Form 8-K is a current report filed by Cerecor Inc. on March 13, 2017. The filing discloses amendments to employment agreements for two senior officers, effective March 9, 2017. Note: The request metadata lists "Avalo Therapeutics, Inc.", but the filing text explicitly identifies the registrant as Cerecor Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial performance data.
Material Changes
The material change reported is the amendment of employment contracts for the following officers:
- Mariam Morris (Chief Financial Officer): Amendment to the agreement dated August 24, 2015.
- Dr. Ronald Marcus (Chief Medical Officer): Amendment to the agreement dated May 5, 2015.
Both amendments stipulate that in the event of a termination without cause, the respective officer will receive continued payment of their base salary (as in effect immediately prior to termination) for a period of one year following such termination.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding business operations or financial projections. The primary contingency disclosed is the potential financial obligation to pay severance (one year of base salary) to the CFO or CMO in the event of a termination without cause. The full text of the amendments is referenced as an exhibit to the upcoming Form 10-Q for the period ended March 31, 2017.
Investor Verification Checklist
- Verify the exact base salary amounts for Mariam Morris and Dr. Ronald Marcus to calculate potential severance liabilities.
- Review the full employment agreement amendments when filed as exhibits to the Form 10-Q for the period ended March 31, 2017.
- Confirm the definition of "termination without cause" within the specific contracts to understand the triggers for these payments.